Novel genes associated with malignant melanoma but not benign melanocytic lesions - PubMed (original) (raw)
Comparative Study
. 2005 Oct 15;11(20):7234-42.
doi: 10.1158/1078-0432.CCR-05-0683.
Affiliations
- PMID: 16243793
- DOI: 10.1158/1078-0432.CCR-05-0683
Comparative Study
Novel genes associated with malignant melanoma but not benign melanocytic lesions
Dmitri Talantov et al. Clin Cancer Res. 2005.
Abstract
Purpose: Cutaneous melanoma is a common, aggressive cancer with increasing incidence. The identification of melanoma-specific deregulated genes could provide molecular markers for lymph node staging assays and further insight into melanoma tumorigenesis.
Experimental design: Total RNA isolated from 45 primary melanoma, 18 benign skin nevi, and 7 normal skin tissue specimens were analyzed on an Affymetrix Hu133A microarray containing 22,000 probe sets.
Results: Hierarchical clustering revealed a distinct separation of the melanoma samples from the benign and normal specimens. Novel genes associated with malignant melanoma were identified. Differential gene expression of two melanoma-specific genes, PLAB and L1CAM, were tested by a one-step quantitative reverse transcription-PCR assay on primary malignant melanoma, benign nevi, and normal skin samples, as well as on malignant melanoma lymph node metastasis and melanoma-free lymph nodes. The performance of the markers was compared with conventional melanoma markers such as tyrosinase, gp100, and MART1.
Conclusion: Our study systematically identified novel melanoma-specific genes and showed the feasibility of using a combination of PLAB and L1CAM in a reverse transcription-PCR assay to differentiate clinically relevant samples containing benign or malignant melanocytes.
Similar articles
- Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction.
Lewis TB, Robison JE, Bastien R, Milash B, Boucher K, Samlowski WE, Leachman SA, Dirk Noyes R, Wittwer CT, Perreard L, Bernard PS. Lewis TB, et al. Cancer. 2005 Oct 15;104(8):1678-86. doi: 10.1002/cncr.21372. Cancer. 2005. PMID: 16116595 - Signatures of microRNAs and selected microRNA target genes in human melanoma.
Philippidou D, Schmitt M, Moser D, Margue C, Nazarov PV, Muller A, Vallar L, Nashan D, Behrmann I, Kreis S. Philippidou D, et al. Cancer Res. 2010 May 15;70(10):4163-73. doi: 10.1158/0008-5472.CAN-09-4512. Epub 2010 May 4. Cancer Res. 2010. PMID: 20442294 - Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A; Melanoma Group of the European Organization for Research and Treatment of Cancer. Winnepenninckx V, et al. J Natl Cancer Inst. 2006 Apr 5;98(7):472-82. doi: 10.1093/jnci/djj103. J Natl Cancer Inst. 2006. PMID: 16595783 - Gene expression profiling of primary cutaneous melanoma.
Winnepenninckx V, Van den Oord JJ. Winnepenninckx V, et al. Verh K Acad Geneeskd Belg. 2007;69(1):23-45. Verh K Acad Geneeskd Belg. 2007. PMID: 17427873 Review. - Gene expression profiling and clinical outcome in melanoma: in search of novel prognostic factors.
Winnepenninckx V, van den Oord JJ. Winnepenninckx V, et al. Expert Rev Anticancer Ther. 2007 Nov;7(11):1611-31. doi: 10.1586/14737140.7.11.1611. Expert Rev Anticancer Ther. 2007. PMID: 18020928 Review.
Cited by
- Mechanism of norcantharidin intervention in gastric cancer: analysis based on antitumor proprietary Chinese medicine database, network pharmacology, and transcriptomics.
Zhai Y, Zhang F, Zhou J, Qiao C, Jin Z, Zhang J, Wu C, Shi R, Huang J, Gao Y, Guo S, Wang H, Chai K, Zhang X, Wang T, Sheng X, Liu X, Wu J. Zhai Y, et al. Chin Med. 2024 Sep 17;19(1):129. doi: 10.1186/s13020-024-01000-1. Chin Med. 2024. PMID: 39289763 Free PMC article. - H2A.Z chaperones converge on E2F target genes for melanoma cell proliferation.
Jostes S, Vardabasso C, Dong J, Carcamo S, Singh R, Phelps R, Meadows A, Grossi E, Hasson D, Bernstein E. Jostes S, et al. Genes Dev. 2024 May 21;38(7-8):336-353. doi: 10.1101/gad.351318.123. Genes Dev. 2024. PMID: 38744503 Free PMC article. - P16-CD8-Ki67 Triple Algorithm for Prediction of CDKN2A Mutations in Patients with Multiple Primary and Familial Melanoma.
Nurla LA, Gheorghe E, Aşchie M, Cozaru GC, Orășanu CI, Boşoteanu M. Nurla LA, et al. Diagnostics (Basel). 2024 Apr 13;14(8):813. doi: 10.3390/diagnostics14080813. Diagnostics (Basel). 2024. PMID: 38667459 Free PMC article. - MAPK-mediated PHGDH induction is essential for melanoma formation and represents an actionable vulnerability.
Jasani N, Xu X, Posorske B, Kim Y, Vera O, Tsai KY, DeNicola GM, Karreth FA. Jasani N, et al. bioRxiv [Preprint]. 2024 Apr 15:2024.04.11.589139. doi: 10.1101/2024.04.11.589139. bioRxiv. 2024. PMID: 38659816 Free PMC article. Preprint. - Integrated in vivo functional screens and multi-omics analyses identify α-2,3-sialylation as essential for melanoma maintenance.
Agrawal P, Chen S, de Pablos A, Jame-Chenarboo F, Miera Saenz de Vega E, Darvishian F, Osman I, Lujambio A, Mahal LK, Hernando E. Agrawal P, et al. bioRxiv [Preprint]. 2024 Mar 12:2024.03.08.584072. doi: 10.1101/2024.03.08.584072. bioRxiv. 2024. PMID: 38559078 Free PMC article. Preprint.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical